

Atherosclerosis International Meeting



HELLENIC
ATHEROSCLEROSIS
SOCIETY



TURKISH
SOCIETY OF
CARDIOLOGY

Atherosclerosis International Meeting 7- 9 September 2018 Chalkidiki, Greece

Friday, 7 September 2018

11.00-11.45 Registrations

11.45-12.00 Introduction – Welcome Messages

L. Tokgozoglu

V. Kotsis

Atherosclerosis and cardiovascular risk update

Chair: A. Tselepis, D. Ural

12.00-12.30 Many faces of atherosclerotic vascular damage. **N. Koylan**

12.30-13.00 Imaging and Biomarkers: Are they really helpful? **N. Ozer**

13.00-13.30 How do we determine risk in 2018? **Z. Ongen**

13.30-14.30 Light Lunch

Atherosclerosis International Meeting

Clinical workshop

- 14.30-15.30** Case presentations from the Turkish Cardiology Society.
Chair: L. Tokgozoglul, M Elisaf
Interactive discussion with participants (4 cases 10 min each, followed by 5 min discussion)

CVD epidemiology and prevention

Chair: V Athyros, M. Kayikcioglu

- 15.30-16.00.** Population aging and cardiovascular disease incidence: 60-years (1950s-2015) experience in Greece. **D. B. Panagiotakos** (Athens, Greece)

- 16.00-16.30.** Precision medicine in 2018 or What is new in prevention? **D. Ural**

- 16.30-16.45** **Coffee Break**

Cardiovascular risk beyond LDL

Chair: C. Savopoulos, N. Koylan

- 16.45-17.15** How important is non-HDL? **L. Tokgozoglul**

- 17.15-17.45** Lp(a). Present and future. **A. Tselepis**

Atherosclerosis International Meeting

17.45-18.15 Nonalcoholic steatohepatitis: the emerging cardiovascular risk factor. **V. G. Athyros**

Dyslipidemias. New treatment options

Chair: D. Panagiotakos, N. Ozer

18.15-18.45 PCSK9 inhibitors in patients with familial hypercholesterolemia.

M. Elisaf

18.45-19.15 How should we manage patients with high triglycerides?

M. Kayikcioglu

Saturday, 8 September 2018

Treatment options and update on statin treatment

Chair. Kotsis V, M. Kayikcioglu

09.00-09.30 How far should we lower LDL? **H. Kultursay**

09.30-10.00 How should we treat patients with type II diabetes and dyslipidemia.

E. Liberopoulos

10.00-10.30 Statins, where are we? **V. Sansoy**

Atherosclerosis International Meeting

10.30-11.00 Statin intolerance. **K. Tziomalos**

11.00-11.30 Coffee Break

11.30-12.00 **Distinguished Lecture**

Chair. A. Tselepis

Shared risk factors for cardiovascular disease and dementia – genetic, epidemiologic, and causal aspects. **R. Frikke-Schmidt**

Clinical workshop

12.00-13.00 Case presentations from the Hellenic Atherosclerosis Society.

Chair: Liberopoulos E, V. Sansoy

Interactive discussion with participants (5 cases 10 min each). (4 cases 10 min each followed by 5 min discussion)

Treatment within co-morbidities: obesity, type II diabetes, hypertension and stroke

Chair. K Tziomalos, Z. Ongen

13.00-13.30 Drug combinations in the treatment of cardiovascular diseases.

V. Kotsis

13.30-14.00 Treatment of diabetes in obesity. **N. Katsiki**

14.00-14.30 Treatment of hypertension and dyslipidemia after acute stroke.

X. Savopoulos

Atherosclerosis International Meeting

Sunday, 9 September 2018

Case report presentation

09.00-09.30 09.30-10.00 Patient with hypertension and dyslipidemia. **V. Kotsis**

10.00-10.30 Patient with CAD and LDLc 85 on atorvaatatin. **M. Kayikcioglu**

10.30-11.00 Obese Patient with a stable angina and Tgs 210 mg/dL. **K.Tziomalos**

11.00-11.30 Patient without treatment with obesity and LDL 210. **V. Athyros**

11.30-12.00 Patient with hypertension, diabetes and LDL 145 mg/dL. **N. Katsiki**

12.00-12.30 Patient with LDL 300mg/dL and family history of early CAD. **L. Tolozoglu**